Biomea Fusion (BMEA) Income from Continuing Operations (2020 - 2026)
Biomea Fusion (BMEA) posted Income from Continuing Operations of 12344000.0 for Q1 2026, up 26.95% sequentially from 16899000.0 in Q4 2025, and up 57.82% YoY from 7821787.09 in Q1 2025.
Biomea Fusion (BMEA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Biomea Fusion has reported Income from Continuing Operations for 7 years, with the latest figure at 12344000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 57.82% year-over-year to 12344000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 66390000.0 (up 48.43% YoY) and the FY2025 annual result came in at 214890000.0, up 14.82% from the prior year.
- Income from Continuing Operations improved to 12344000.0 in Q1 2026 per BMEA's latest filing, from 16899000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 12344000.0 in Q1 2026 and troughed at 45337000.0 in Q3 2023.
- A 5-year average of 27850352.94 and a median of 29262000.0 in 2025 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2026: Income from Continuing Operations slumped 145.42% in 2023, then surged 57.82% in 2026.
- Over 5 years, Income from Continuing Operations stood at 25487000.0 in 2022, then plunged by 35.3% to 34483000.0 in 2023, then grew by 14.68% to 29421000.0 in 2024, then jumped by 42.56% to 16899000.0 in 2025, then grew by 26.95% to 12344000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 12344000.0, 16899000.0, and 16407000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Biomea Fusion | 97.69 Mn | 97.69 Mn | - | -12.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.45 Mn |
| Mar 31, 2026 | -12.34 Mn |
| Dec 31, 2025 | -16.90 Mn |
| Sep 30, 2025 | -16.41 Mn |
| Jun 30, 2025 | -20.74 Mn |
| Mar 31, 2025 | -29.26 Mn |
| Dec 31, 2024 | -29.42 Mn |
| Sep 30, 2024 | -32.79 Mn |
| Jun 30, 2024 | -37.28 Mn |
| Mar 31, 2024 | -43.30 Mn |
| Dec 31, 2023 | -34.48 Mn |
| Sep 30, 2023 | -45.34 Mn |
| Jun 30, 2023 | -42.79 Mn |
| Mar 31, 2023 | -29.89 Mn |
| Dec 31, 2022 | -25.49 Mn |
| Sep 30, 2022 | -23.07 Mn |
| Jun 30, 2022 | -17.43 Mn |
| Mar 31, 2022 | -16.54 Mn |
| Dec 31, 2021 | -14.86 Mn |
| Sep 30, 2021 | -15.99 Mn |